1
|
Fairfax SR, Yang S. Distributional imputation for the analysis of censored recurrent events. Stat Med 2024; 43:2622-2640. [PMID: 38684331 PMCID: PMC11327775 DOI: 10.1002/sim.10087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 03/29/2024] [Accepted: 04/13/2024] [Indexed: 05/02/2024]
Abstract
Longitudinal clinical trials for which recurrent events endpoints are of interest are commonly subject to missing event data. Primary analyses in such trials are often performed assuming events are missing at random, and sensitivity analyses are necessary to assess robustness of primary analysis conclusions to missing data assumptions. Control-based imputation is an attractive approach in superiority trials for imposing conservative assumptions on how data may be missing not at random. A popular approach to implementing control-based assumptions for recurrent events is multiple imputation (MI), but Rubin's variance estimator is often biased for the true sampling variability of the point estimator in the control-based setting. We propose distributional imputation (DI) with corresponding wild bootstrap variance estimation procedure for control-based sensitivity analyses of recurrent events. We apply control-based DI to a type I diabetes trial. In the application and simulation studies, DI produced more reasonable standard error estimates than MI with Rubin's combining rules in control-based sensitivity analyses of recurrent events.
Collapse
Affiliation(s)
- Sarah R Fairfax
- Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA
| | - Shu Yang
- Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA
| |
Collapse
|
2
|
Lee D, Gao C, Ghosh S, Yang S. Transporting survival of an HIV clinical trial to the external target populations. J Biopharm Stat 2024:1-22. [PMID: 38520697 DOI: 10.1080/10543406.2024.2330216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2024] [Accepted: 02/20/2024] [Indexed: 03/25/2024]
Abstract
Due to the heterogeneity of the randomized controlled trial (RCT) and external target populations, the estimated treatment effect from the RCT is not directly applicable to the target population. For example, the patient characteristics of the ACTG 175 HIV trial are significantly different from that of the three external target populations of interest: US early-stage HIV patients, Thailand HIV patients, and southern Ethiopia HIV patients. This paper considers several methods to transport the treatment effect from the ACTG 175 HIV trial to the target populations beyond the trial population. Most transport methods focus on continuous and binary outcomes; on the contrary, we derive and discuss several transport methods for survival outcomes: an outcome regression method based on a Cox proportional hazard (PH) model, an inverse probability weighting method based on the models for treatment assignment, sampling score, and censoring, and a doubly robust method that combines both methods, called the augmented calibration weighting (ACW) method. However, as the PH assumption was found to be incorrect for the ACTG 175 trial, the methods that depend on the PH assumption may lead to the biased quantification of the treatment effect. To account for the violation of the PH assumption, we extend the ACW method with the linear spline-based hazard regression model that does not require the PH assumption. Applying the aforementioned methods for transportability, we explore the effect of PH assumption, or the violation thereof, on transporting the survival results from the ACTG 175 trial to various external populations.
Collapse
Affiliation(s)
- Dasom Lee
- Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA
| | - Chenyin Gao
- Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA
| | - Sujit Ghosh
- Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA
| | - Shu Yang
- Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA
| |
Collapse
|
3
|
Liu S, Yang S, Zhang Y, Liu G(F. Multiply robust estimators in longitudinal studies with missing data under control-based imputation. Biometrics 2024; 80:ujad036. [PMID: 38393335 PMCID: PMC10885818 DOI: 10.1093/biomtc/ujad036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 12/05/2023] [Accepted: 12/19/2023] [Indexed: 02/25/2024]
Abstract
Longitudinal studies are often subject to missing data. The recent guidance from regulatory agencies, such as the ICH E9(R1) addendum addresses the importance of defining a treatment effect estimand with the consideration of intercurrent events. Jump-to-reference (J2R) is one classical control-based scenario for the treatment effect evaluation, where the participants in the treatment group after intercurrent events are assumed to have the same disease progress as those with identical covariates in the control group. We establish new estimators to assess the average treatment effect based on a proposed potential outcomes framework under J2R. Various identification formulas are constructed, motivating estimators that rely on different parts of the observed data distribution. Moreover, we obtain a novel estimator inspired by the efficient influence function, with multiple robustness in the sense that it achieves n1/2-consistency if any pairs of multiple nuisance functions are correctly specified, or if the nuisance functions converge at a rate not slower than n-1/4 when using flexible modeling approaches. The finite-sample performance of the proposed estimators is validated in simulation studies and an antidepressant clinical trial.
Collapse
Affiliation(s)
- Siyi Liu
- Department of Statistics, North Carolina State University, Raleigh, NC 27607, United States
| | - Shu Yang
- Department of Statistics, North Carolina State University, Raleigh, NC 27607, United States
| | - Yilong Zhang
- Merck & Co., Inc., Kenilworth, NJ 07033, United States
| | | |
Collapse
|
4
|
Liu S, Zhang Y, Golm GT, Liu G(F, Yang S. Robust analyzes for longitudinal clinical trials with missing and non-normal continuous outcomes. STATISTICAL THEORY AND RELATED FIELDS 2023; 8:1-14. [PMID: 38800501 PMCID: PMC11115336 DOI: 10.1080/24754269.2023.2261351] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 09/16/2023] [Indexed: 05/29/2024]
Abstract
Missing data is unavoidable in longitudinal clinical trials, and outcomes are not always normally distributed. In the presence of outliers or heavy-tailed distributions, the conventional multiple imputation with the mixed model with repeated measures analysis of the average treatment effect (ATE) based on the multivariate normal assumption may produce bias and power loss. Control-based imputation (CBI) is an approach for evaluating the treatment effect under the assumption that participants in both the test and control groups with missing outcome data have a similar outcome profile as those with an identical history in the control group. We develop a robust framework to handle non-normal outcomes under CBI without imposing any parametric modeling assumptions. Under the proposed framework, sequential weighted robust regressions are applied to protect the constructed imputation model against non-normality in the covariates and the response variables. Accompanied by the subsequent mean imputation and robust model analysis, the resulting ATE estimator has good theoretical properties in terms of consistency and asymptotic normality. Moreover, our proposed method guarantees the analysis model robust-ness of the ATE estimation in the sense that its asymptotic results remain intact even when the analysis model is misspecified. The superiority of the proposed robust method is demonstrated by comprehensive simulation studies and an AIDS clinical trial data application.
Collapse
Affiliation(s)
- Siyi Liu
- Department of Statistics, North Carolina State University, Raleigh, NC, USA
| | | | | | | | - Shu Yang
- Department of Statistics, North Carolina State University, Raleigh, NC, USA
| |
Collapse
|
5
|
Tompsett D, Zylbersztejn A, Hardelid P, De Stavola B. Target Trial Emulation and Bias Through Missing Eligibility Data: An Application to a Study of Palivizumab for the Prevention of Hospitalization Due to Infant Respiratory Illness. Am J Epidemiol 2023; 192:600-611. [PMID: 36509514 PMCID: PMC10089079 DOI: 10.1093/aje/kwac202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 08/11/2022] [Accepted: 11/09/2022] [Indexed: 12/15/2022] Open
Abstract
Target trial emulation (TTE) applies the principles of randomized controlled trials to the causal analysis of observational data sets. One challenge that is rarely considered in TTE is the sources of bias that may arise if the variables involved in the definition of eligibility for the trial are missing. We highlight patterns of bias that might arise when estimating the causal effect of a point exposure when restricting the target trial to individuals with complete eligibility data. Simulations consider realistic scenarios where the variables affecting eligibility modify the causal effect of the exposure and are missing at random or missing not at random. We discuss means to address these patterns of bias, namely: 1) controlling for the collider bias induced by the missing data on eligibility, and 2) imputing the missing values of the eligibility variables prior to selection into the target trial. Results are compared with the results when TTE is performed ignoring the impact of missing eligibility. A study of palivizumab, a monoclonal antibody recommended for the prevention of respiratory hospital admissions due to respiratory syncytial virus in high-risk infants, is used for illustration.
Collapse
Affiliation(s)
- Daniel Tompsett
- Correspondence to Dr. Daniel Tompsett, Population Policy and Practice Department, UCL GOS Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, United Kingdom (e-mail: )
| | | | | | | |
Collapse
|
6
|
Liu S, Yang S, Zhang Y, Liu G(F. Sensitivity analyses in longitudinal clinical trials via distributional imputation. Stat Methods Med Res 2023; 32:181-194. [PMID: 36341772 PMCID: PMC10950063 DOI: 10.1177/09622802221135251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Missing data is inevitable in longitudinal clinical trials. Conventionally, the missing at random assumption is assumed to handle missingness, which however is unverifiable empirically. Thus, sensitivity analyses are critically important to assess the robustness of the study conclusions against untestable assumptions. Toward this end, regulatory agencies and the pharmaceutical industry use sensitivity models such as return-to-baseline, control-based, and washout imputation, following the ICH E9(R1) guidance. Multiple imputation is popular in sensitivity analyses; however, it may be inefficient and result in an unsatisfying interval estimation by Rubin's combining rule. We propose distributional imputation in sensitivity analysis, which imputes each missing value by samples from its target imputation model given the observed data. Drawn on the idea of Monte Carlo integration, the distributional imputation estimator solves the mean estimating equations of the imputed dataset. It is fully efficient with theoretical guarantees. Moreover, we propose weighted bootstrap to obtain a consistent variance estimator, taking into account the variabilities due to model parameter estimation and target parameter estimation. The superiority of the distributional imputation framework is validated in the simulation study and an antidepressant longitudinal clinical trial.
Collapse
Affiliation(s)
- Siyi Liu
- Department of Statistics, North Carolina State University, Raleigh, NC, USA
| | - Shu Yang
- Department of Statistics, North Carolina State University, Raleigh, NC, USA
| | | | | |
Collapse
|
7
|
Lee D, Yang S, Wang X. Doubly robust estimators for generalizing treatment effects on survival outcomes from randomized controlled trials to a target population. JOURNAL OF CAUSAL INFERENCE 2022; 10:415-440. [PMID: 37637433 PMCID: PMC10457100 DOI: 10.1515/jci-2022-0004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 08/29/2023]
Abstract
In the presence of heterogeneity between the randomized controlled trial (RCT) participants and the target population, evaluating the treatment effect solely based on the RCT often leads to biased quantification of the real-world treatment effect. To address the problem of lack of generalizability for the treatment effect estimated by the RCT sample, we leverage observational studies with large samples that are representative of the target population. This article concerns evaluating treatment effects on survival outcomes for a target population and considers a broad class of estimands that are functionals of treatment-specific survival functions, including differences in survival probability and restricted mean survival times. Motivated by two intuitive but distinct approaches, i.e., imputation based on survival outcome regression and weighting based on inverse probability of sampling, censoring, and treatment assignment, we propose a semiparametric estimator through the guidance of the efficient influence function. The proposed estimator is doubly robust in the sense that it is consistent for the target population estimands if either the survival model or the weighting model is correctly specified and is locally efficient when both are correct. In addition, as an alternative to parametric estimation, we employ the nonparametric method of sieves for flexible and robust estimation of the nuisance functions and show that the resulting estimator retains the root-n consistency and efficiency, the so-called rate-double robustness. Simulation studies confirm the theoretical properties of the proposed estimator and show that it outperforms competitors. We apply the proposed method to estimate the effect of adjuvant chemotherapy on survival in patients with early-stage resected non-small cell lung cancer.
Collapse
Affiliation(s)
- Dasom Lee
- Department of Statistics, North Carolina State University, Raleigh, NC 27695, United States
| | - Shu Yang
- Department of Statistics, North Carolina State University, Raleigh, NC 27695, United States
| | - Xiaofei Wang
- Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 27708, United States
| |
Collapse
|